Top Markets
#1 Purr Purr +59.29%
#2 Smilek to the Bank Smilek to the Bank +50.56%
#3 Pons Pons +32.91%
#4 Kinetiq Kinetiq +30.53%
#5 ApeX ApeX +25.45%
#6 Non-Playable Coin Non-Playable Coin +21.19%
#7 OriginTrail OriginTrail +19.37%
#8 Morpho Morpho +18.34%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +18.17%
#10 Fake World Assets Fake World Assets +18.14%
Coin of the day
Purr Purr
Settings
Language
ENGLISH
Currency
USD
Theme
CANbridge Pharmaceuticals Inc. CANbridge Pharmaceuticals Inc.

CANbridge Pharmaceuticals Inc.

1228
Rank in Stocks #21199
CANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on the... CANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on the global research, development, and commercialization of treatments for rare disorders and various cancer types. The company's marketed products include Hunterase, an enzyme replacement therapy for Hunter syndrome; NERLYNX (Neratinlib), a powerful, irreversible tyrosine kinase inhibitor targeting HER2-positive breast cancer; and Caphosol Mouth Rinse, used to alleviate temporary and persistent dry mouth and throat. Its robust development pipeline features several investigational therapies: CAN008, an artificially engineered antibody-like fully human fusion protein being developed for glioblastoma multiforme; CAN108, an orally administered reversible inhibitor of the ileal bile acid transporter, designed to treat rare cholestatic liver diseases; CAN106, a humanized monoclonal antibody against complement C5 for complement-mediated conditions; CAN103 and CAN104, both recombinant human enzyme replacement therapies (ERTs); CAN105, a bispecific antibody; and gene therapy programs CAN201 and CAN202, both utilizing adeno-associated virus (AAV) sL65 capsid technology. Established in 2012, CANbridge Pharmaceuticals Inc. is based in Beijing, China.
Share Price
$0.26544693
Last synced: 2026-08-21
Market Cap
$112.77M
Change (1 day)
-0.72%
Change (1 year)
-16.36%
Country
CN
Trade CANbridge Pharmaceuticals Inc. (1228)

Category

Healthcare
Revenue for CANbridge Pharmaceuticals Inc. (1228)
Revenue in Aug 2026 TTM: 0
According to CANbridge Pharmaceuticals Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for CANbridge Pharmaceuticals Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH